A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early-Stage Parkinson's Disease
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early-Stage Parkinson's Disease
The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics (PK) of prasinezumab compared with placebo in participants with early-stage Parkinson's disease (PD) on stable symptomatic monotherapy with levodopa.
Inclusion Criteria:
Exclusion Criteria:
global-roche-genentech-trials@gene.com888-662-6728 (U.S. and Canada)
Palo Alto, California 94301, United States
Pasadena, California 91105, United States
Boca Raton, Florida 33486, United States
Paramus, New Jersey 07652, United States
Commack, New York 11725, United States
Prahan, Victoria 3181, Australia
Nedlands, Western Australia 6009, Australia
Ribeirão Preto, São Paulo 14051-140, Brazil
São José do Rio Preto, São Paulo 15090-000, Brazil
Beijing, 100050, China
Hangzhou, 310009, China
Shanghai, 200127, China
Xi'an, 710061, China
Freiburg im Breisgau, 79106, Germany
Heidelberg, 69120, Germany
Würzburg, 97080, Germany
Mexico City, Mexico CITY (federal District) 14390, Mexico
Bia?ystok, 15-756, Poland
Gda?sk, 80-462, Poland
Changhua County, 500, Taiwan
North Dist., 40447, Taiwan